PAREXEL Simplifies Drug Development Journey From Science To New Treatments
“Your Journey. Our Mission.™” communicates company’s new brand promise
Boston, MA, February 12, 2014 — As the global biopharmaceutical industry increasingly seeks to streamline the complex process of bringing new drugs to market, PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced the launch of a new marketing initiative that highlights the Company’s proven approach to help clients simplify the journey from science to new treatments.
Drug development today is a demanding and difficult process. Increasingly, pharmaceutical companies are under pressure to accelerate development and introduce innovative new medicines and treatments in an increasingly complex and competitive environment. To assist in these efforts, companies are seeking a partner that can help simplify and accelerate all aspects of product development.
“In today’s market, biopharmaceutical companies must effectively balance global requirements with regional and local issues, address clinical trial complexity and seek ways to make the drug development process more efficient,” said Josef von Rickenbach, Chairman and Chief Executive Officer, PAREXEL International. “For more than 30 years, our mission has been to help the biopharmaceutical and medical device industries prevent and cure disease. While that mission hasn’t changed, the way we promote our mission is changing. PAREXEL’s new brand platform clearly defines how we can simplify drug development by applying our unique capabilities to the work we do. This will help clients better understand the full scope of our portfolio, and how individual offerings interrelate.”
Your Journey. Our Mission.™
PAREXEL’s new brand promise, “Your Journey. Our Mission™,” represents the Company’s commitment to make each client’s journey its mission. The Company works to fulfill this commitment through its:
- Global Expertise: Today, it is not enough to have a large global footprint. PAREXEL’s drug development experts are connected through common processes, standards and technology, so regardless of where a study is conducted, the same standards of quality apply. With 76 locations in 50 countries, PAREXEL cooperates and collaborates globally to provide services and share best practices around the world. PAREXEL brings value to clients throughout the entire product life cycle by putting to work its deep understanding of science, technology, regulatory and business issues combined with global resources and local knowledge of region-specific requirements.
- Drive to Solve the Complex: From its fully integrated Perceptive MyTrials®eClinical technology platform to its pioneering regulatory work in biosimilars, PAREXEL is constantly working to solve complex challenges for clients by optimizing integrated offerings in new and innovative ways.
- Recognition of the Bigger Journey: PAREXEL led the development of Strategic Partnerships in the biopharmaceutical industry, enabling companies to optimize the entire drug development process. These close, long-term partnerships drive deeper collaboration, speed up development cycles and reduce cost, according to PAREXEL’s Strategic Partnerships 2013 report. It revealed that 85 percent of the biopharmaceutical executives surveyed believe Strategic Partnerships have positively impacted CRO-sponsorship relationships.
As part of its global marketing and advertising campaign, PAREXEL has also launched a new corporate website that provides an enhanced visitor experience, more clearly distinguishes PAREXEL’s products and services, and communicates the Company’s true value to clients. The website features several videos that illustrate the company’s global expertise as well as its ability to manage complexity and develop meaningful Strategic Partnerships.
“We believe the world will be a healthier place when the journey between science and new treatments becomes simpler,” said Christopher Tama, Worldwide Head of Marketing, PAREXEL. “This belief is the foundation of our story, which we are now beginning to tell in new and creative ways.”
# # #
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 76 locations in 50 countries around the world, and has 15,100 employees. For more information about PAREXEL International, visit www.PAREXEL.com.
PAREXEL, PAREXEL Informatics, Perceptive, Perceptive MyTrials, Perceptive Informatics, and “Your Journey. Our Mission.” are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates.
This release contains “forward-looking” statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions, and to integrate newly acquired businesses including the recent acquisitions of LIQUENT, Inc. and HERON, Inc., or enter into new lines of business; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2013 as filed with the SEC on January 31, 2014, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.